The Biogen laboratory hoped to make it the first approved treatment in the field of Alzheimer’s disease for seventeen years. Experts from the American Medicines Agency (FDA) finally issued an unfavorable opinion on Friday to the authorization of aducanumab, a monoclonal antibody intended to slow the progression of the disease, judging insufficient evidence of its effectiveness. An unexpected outcome: two days earlier, the FDA had published on its site encouraging documents for the pharmaceutical company, leading to a 40% increase in its share price. However, the opinion is advisory. The Pr Marie Sarazin heads the department of memory and language neurology at Sainte-Anne hospital in Paris. She deciphers this decision.
LE FIGARO. – Are you disappointed by this unfavorable opinion?
Marie SARAZIN. – Unfortunately, this was to be feared, as the scientific process leading to the authorization request was so controversial. It should be remembered that Biogen